1
|
Burande A, Fine N, Miller RJ, Hahn C, Mahe E, Bosley D, Litwin L, Jimenez-Zepeda VH. Role of a Multidisciplinary Program (Amyloidosis Program of Calgary) on Recognition and Intervention for AL and ATTR Amyloidosis. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2025:S2152-2650(25)00140-5. [PMID: 40379497 DOI: 10.1016/j.clml.2025.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2024] [Revised: 04/05/2025] [Accepted: 04/08/2025] [Indexed: 05/19/2025]
Abstract
BACKGROUND The diagnosis and management of amyloidosis requires strong coordination among various teams and a multidisciplinary approach which is essential for providing the diagnostic tools needed for patients with organ amyloid deposition. METHODS In this study, we reviewed the referral patterns to the cardiac and hematology amyloid clinics since the inception of the Amyloidosis Program of Calgary (APC) in 2019. The APC was established to facilitate the diagnosis and treatment of amyloidosis. Additionally, a central referral system was created to expedite the triage of cases with potential amyloid-related symptoms. RESULTS The cardiac amyloid clinic saw an increase in referrals from 41 in 2018 to 105 in 2022, although there was a temporary decrease from 67 in 2019 to 56 in 2020 during the first year of the pandemic. Most referrals came from nonamyloid cardiology clinics, followed by hematology referrals. Fifty percent of the cases referred were patients with ATTR and 18% represented AL cases. Moreover, amyloid clinic at our cancer center also began receiving referrals via the central triage system in 2019, with AL amyloidosis cases increasing from 16 to 25 between 2018 and 2023. Therefore, we report here the significant impact of the APC on increasing referrals for patients with ATTR, with the program facilitating diagnostic pathways for these rare conditions. IN SUMMARY Since 2022, the establishment of an amyloid screening clinic has furthered these efforts, aiming to enhance early recognition and improve clinical outcomes.
Collapse
Affiliation(s)
- Aksha Burande
- Department of Medical Oncology and Hematology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada
| | - Nowell Fine
- Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada
| | - Robert Jh Miller
- Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada
| | - Christopher Hahn
- Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
| | - Etienne Mahe
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Debra Bosley
- Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada
| | - Lyndsay Litwin
- Department of Cardiac Sciences, Division of Cardiology, Libin Cardiovascular Institute, Calgary, Alberta, Canada
| | - Victor H Jimenez-Zepeda
- Department of Medical Oncology and Hematology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Arnie Charbonneau Research Institute, University of Calgary, Calgary, AB, Canada.
| |
Collapse
|
2
|
Martinez-Lucio TS, Mendoza-Ibañez OI, Liu W, Mostafapour S, Li Z, Providência L, Salvi de Souza G, Mohr P, Dobrolinska MM, van Leer B, Tingen HSA, van Sluis J, Tsoumpas C, Glaudemans AWJM, Koopmans KP, Lammertsma AA, Slart RHJA. Long Axial Field of View PET/CT: Technical Aspects in Cardiovascular Diseases. Semin Nucl Med 2025; 55:52-66. [PMID: 39537432 DOI: 10.1053/j.semnuclmed.2024.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2024] [Accepted: 10/16/2024] [Indexed: 11/16/2024]
Abstract
Positron emission tomography / computed tomography (PET/CT) plays a pivotal role in the assessment of cardiovascular diseases (CVD), particularly in the context of ischemic heart disease. Nevertheless, its application in other forms of CVD, such as infiltrative, infectious, or inflammatory conditions, remains limited. Recently, PET/CT systems with an extended axial field of view (LAFOV) have been developed, offering greater anatomical coverage and significantly enhanced PET sensitivity. These advancements enable head-to-pelvis imaging with a single bed position, and in systems with an axial field of view (FOV) of approximately 2 meters, even total body (TB) imaging is feasible in a single scan session. The application of LAFOV PET/CT in CVD presents a promising opportunity to improve systemic cardiovascular assessments and address the limitations inherent to conventional short axial field of view (SAFOV) devices. However, several technical challenges, including procedural considerations for LAFOV systems in CVD, complexities in data processing, arterial input function extraction, and artefact management, have not been fully explored. This review aims to discuss the technical aspects of LAFOV PET/CT in relation to CVD by highlighting key opportunities and challenges and examining the impact of these factors on the evaluation of most relevant CVD.
Collapse
Affiliation(s)
- Tonantzin Samara Martinez-Lucio
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Oscar Isaac Mendoza-Ibañez
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Wanling Liu
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Samaneh Mostafapour
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Zekai Li
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Laura Providência
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Giordana Salvi de Souza
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Philipp Mohr
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Magdalena M Dobrolinska
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Division of Cardiology and Structural Heart Diseases, Medical University of Silesia in Katowice, Katowice, Poland
| | - Bram van Leer
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Hendrea S A Tingen
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Joyce van Sluis
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Charalampos Tsoumpas
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Andor W J M Glaudemans
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Klaas Pieter Koopmans
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Adriaan A Lammertsma
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Riemer H J A Slart
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Department of Biomedical Photonic Imaging, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.
| |
Collapse
|
3
|
Xing Y, Li X, Zhao J, Wu H, Zhao L, Zheng W, Sun S. Advancing precision medicine in immunoglobulin light-chain amyloidosis: a novel prognostic model incorporating multi-organ indicators. Intern Emerg Med 2024; 19:1335-1344. [PMID: 38743128 DOI: 10.1007/s11739-024-03621-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Accepted: 04/17/2024] [Indexed: 05/16/2024]
Abstract
To develop a more accurate prognostic model that incorporates indicators of multi-organ involvement for immunoglobulin light-chain (AL) Amyloidosis patients. Biopsy-proven AL amyloidosis patients between January 1, 2012, and February 28, 2023, were enrolled and randomly divided into a training set and a test set at a ratio of 7:3. Prognostic indicators that comprehensively cover cardiac, renal, and hepatic involvement were identified in the training set by random survival forest (RSF). Then, RSF and Cox models were established. The Concordance index (C-index) and integrated brier scores (IBS) were applied to evaluate the models' performance in the test set. Besides, the net reclassification index (NRI) and integrated discrimination improvement (IDI) were calculated. A total of 173 eligible patients were included. After a median follow-up of 25.9 (9.2, 50.3) months, 48 (27.7%) patients died. Creatine kinase-MB, estimated glomerular filtration rate ≤ 50 mL/min/1.73 m2, interventricular septum ≥ 15 mm, ejection fraction, alanine aminotransferase and Live involved were selected to develop prediction models. The RSF model based on the above indicators achieved C-index and IBS values of 0.834 (95% CI 0.725-0.915) and 0.151 (95% CI 0.1402-0.181), respectively. At last, the NRI and IDI of the RSF model were 0.301 (95% CI 0.048-0.546, P = 0.012) and 0.157 (95% CI 0.041-0.269, P < 0.001) at 5-year by comparing the RSF model with the Cox model which is based on the Mayo 2012 staging system. The RSF model that incorporates indicators of multi-organ involvement had a great performance, which may be helpful for physicians' decision-making and more accurate overall survival prediction.
Collapse
Affiliation(s)
- Yan Xing
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, No.127 Chang Le West Road, Xi'an, 710032, Shaanxi, China
| | - Xiayin Li
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, No.127 Chang Le West Road, Xi'an, 710032, Shaanxi, China
| | - Jin Zhao
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, No.127 Chang Le West Road, Xi'an, 710032, Shaanxi, China
| | - Hao Wu
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, No.127 Chang Le West Road, Xi'an, 710032, Shaanxi, China
| | - Lijuan Zhao
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, No.127 Chang Le West Road, Xi'an, 710032, Shaanxi, China
| | - Wanting Zheng
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, No.127 Chang Le West Road, Xi'an, 710032, Shaanxi, China
| | - Shiren Sun
- Department of Nephrology, Xijing Hospital, The Fourth Military Medical University, No.127 Chang Le West Road, Xi'an, 710032, Shaanxi, China.
| |
Collapse
|
4
|
D'Souza A. Amyloid consults do not have to be vexing. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2023; 2023:407-412. [PMID: 38066929 PMCID: PMC10727086 DOI: 10.1182/hematology.2023000440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2023]
Abstract
Diagnosing amyloidosis can be challenging due to its clinical heterogeneity, need for multiple specialists to make a diagnosis, and lack of a single diagnostic test for the disease. Patients are often diagnosed late, in advanced stage, and after exhibiting multiple symptoms and signs for a long period. It is important to develop a clinical suspicion of amyloidosis, particularly in those with multisystemic symptoms and high-risk patient populations such as those with precursor hematologic conditions. A systematic approach to the workup of suspected amyloidosis is key, including a comprehensive clinical assessment, laboratory tests to assess organ involvement, advanced imaging studies, screening for plasma cell disorder, and tissue biopsy when necessary. After making a diagnosis of amyloidosis, accurate typing of amyloid deposits, differentiating between localized and systemic amyloidosis, and appropriately staging the disease is important. Early diagnosis is crucial for improving patient outcomes and quality of life in light chain amyloidosis.
Collapse
Affiliation(s)
- Anita D'Souza
- Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
| |
Collapse
|